Intra-Cellular Therapies Inc (ITCI)
85.45
-0.19
(-0.22%)
USD |
NASDAQ |
Nov 21, 16:00
85.51
+0.06
(+0.07%)
After-Hours: 20:00
Intra-Cellular Therapies Gross Profit Margin (Quarterly): 91.26% for Sept. 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 91.26% |
| June 30, 2024 | 92.96% |
| March 31, 2024 | 93.16% |
| December 31, 2023 | 91.86% |
| September 30, 2023 | 92.74% |
| June 30, 2023 | 93.50% |
| March 31, 2023 | 92.87% |
| December 31, 2022 | 92.24% |
| September 30, 2022 | 91.86% |
| June 30, 2022 | 91.56% |
| Date | Value |
|---|---|
| March 31, 2022 | 90.92% |
| December 31, 2021 | 90.05% |
| September 30, 2021 | 90.74% |
| June 30, 2021 | 89.27% |
| March 31, 2021 | 90.66% |
| December 31, 2020 | 90.80% |
| September 30, 2020 | 92.45% |
| June 30, 2020 | 93.15% |
| March 31, 2020 | 92.15% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
89.27%
Minimum
Jun 2021
93.50%
Maximum
Jun 2023
91.80%
Average
91.86%
Median
Dec 2023
Gross Profit Margin (Quarterly) Benchmarks
| Ionis Pharmaceuticals Inc | 99.20% |
| AbbVie Inc | 70.87% |
| NovaBay Pharmaceuticals Inc | 65.26% |
| Palatin Technologies Inc | -- |
| iBio Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -10.58% |
| Return on Assets | -8.93% |
| Return on Invested Capital | -10.58% |
| Profit Margin (Quarterly) | -15.03% |
| Operating Margin (Quarterly) | -22.18% |
| Return on Net Operating Assets | -52.09% |